Harbin Medisan Pharmaceutical Co Ltd Net Assets
Harbin Medisan Pharmaceutical Co Ltd net assets. Based on the latest financial reports, Harbin Medisan Pharmaceutical Co Ltd (002900) has net assets worth CN¥1.90 Billion CNY (≈ $278.76 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥3.61 Billion ≈ $528.15 Million USD) and total liabilities (CN¥1.70 Billion ≈ $249.39 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 002900 net assets growth trend to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.90 Billion |
| % of Total Assets | 52.78% |
| Annual Growth Rate | 16.6% |
| 5-Year Change | 20.8% |
| 10-Year Change | 197.29% |
| Growth Volatility | 37.0 |
Net Assets of Harbin Medisan Pharmaceutical Co Ltd (2012–2024)
Net assets of Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024. This chart illustrates how Harbin Medisan Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. See Harbin Medisan Pharmaceutical Co Ltd (002900) balance sheet quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Harbin Medisan Pharmaceutical Co Ltd (2012–2024)
The table below shows the annual net assets of Harbin Medisan Pharmaceutical Co Ltd from 2012 to 2024. For live market cap and overall valuation, see Harbin Medisan Pharmaceutical Co Ltd stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.16 Billion ≈ $316.68 Million |
+0.74% |
| 2023-12-31 | CN¥2.15 Billion ≈ $314.35 Million |
+4.69% |
| 2022-12-31 | CN¥2.05 Billion ≈ $300.27 Million |
-3.05% |
| 2021-12-31 | CN¥2.12 Billion ≈ $309.71 Million |
+18.13% |
| 2020-12-31 | CN¥1.79 Billion ≈ $262.16 Million |
-3.25% |
| 2019-12-31 | CN¥1.85 Billion ≈ $270.96 Million |
-6.00% |
| 2018-12-31 | CN¥1.97 Billion ≈ $288.24 Million |
+7.35% |
| 2017-12-31 | CN¥1.83 Billion ≈ $268.51 Million |
+127.05% |
| 2016-12-31 | CN¥808.17 Million ≈ $118.26 Million |
+11.02% |
| 2015-12-31 | CN¥727.97 Million ≈ $106.53 Million |
+19.50% |
| 2014-12-31 | CN¥609.16 Million ≈ $89.14 Million |
+66.84% |
| 2013-12-31 | CN¥365.13 Million ≈ $53.43 Million |
+6.54% |
| 2012-12-31 | CN¥342.72 Million ≈ $50.15 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Harbin Medisan Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 96.1% over the analyzed period, indicating profitable operations and earnings retention.
Harbin Medisan Pharmaceutical Co Ltd Net Assets Breakdown (December 2024)
Harbin Medisan Pharmaceutical Co Ltd net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥608.34 Million | 28.16% |
| Common Stock | CN¥316.36 Million | 14.65% |
| Other Components | CN¥1.24 Billion | 57.19% |
| Total Equity | CN¥2.16 Billion | 100.00% |
Harbin Medisan Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Harbin Medisan Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Shine-Link Intl
SHG:603648
|
$459.79 Million |
|
DINGDONG CAYMAN 2ADR/3 A
F:945
|
$459.79 Million |
|
Guangdong Ganhua Science & Industry Co Ltd
SHE:000576
|
$459.80 Million |
|
Xinjiang Tianrun Dairy Co Ltd
SHG:600419
|
$459.85 Million |
|
JMT Network Services Public Company Limited
BK:JMT
|
$459.54 Million |
|
ProCredit Holding AG & Co KGaA
XETRA:PCZ
|
$459.41 Million |
|
Guangdong Shirongzhaoye Co Ltd
SHE:002016
|
$459.38 Million |
|
Shanghai Kinlita Chemical Co
SHE:300225
|
$459.16 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Harbin Medisan Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,140,492,171 to 2,160,120,383, a change of 19,628,212 (0.9%).
- Net income of 58,675,175 contributed positively to equity growth.
- Dividend payments of 104,561,518 reduced retained earnings.
- Share repurchases of 217,100 reduced equity.
- Other factors increased equity by 65,731,655.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥58.68 Million | +2.72% |
| Dividends Paid | CN¥104.56 Million | -4.84% |
| Share Repurchases | CN¥217.10K | -0.01% |
| Other Changes | CN¥65.73 Million | +3.04% |
| Total Change | CN¥- | 0.92% |
Book Value vs Market Value Analysis
This analysis compares Harbin Medisan Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.42x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.61x to 1.42x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥1.50 | CN¥9.93 | x |
| 2013-12-31 | CN¥1.63 | CN¥9.93 | x |
| 2014-12-31 | CN¥2.62 | CN¥9.93 | x |
| 2015-12-31 | CN¥3.06 | CN¥9.93 | x |
| 2016-12-31 | CN¥3.41 | CN¥9.93 | x |
| 2017-12-31 | CN¥7.19 | CN¥9.93 | x |
| 2018-12-31 | CN¥6.15 | CN¥9.93 | x |
| 2019-12-31 | CN¥5.90 | CN¥9.93 | x |
| 2020-12-31 | CN¥5.73 | CN¥9.93 | x |
| 2021-12-31 | CN¥6.78 | CN¥9.93 | x |
| 2022-12-31 | CN¥6.45 | CN¥9.93 | x |
| 2023-12-31 | CN¥6.97 | CN¥9.93 | x |
| 2024-12-31 | CN¥6.99 | CN¥9.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Harbin Medisan Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 2.72%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.18%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.76x
- Recent ROE (2.72%) is below the historical average (13.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 24.63% | 16.84% | 0.68x | 2.14x | CN¥49.13 Million |
| 2013 | 28.59% | 17.36% | 0.70x | 2.35x | CN¥67.88 Million |
| 2014 | 24.13% | 21.57% | 0.70x | 1.59x | CN¥86.07 Million |
| 2015 | 22.84% | 23.03% | 0.69x | 1.45x | CN¥93.50 Million |
| 2016 | 21.68% | 23.02% | 0.65x | 1.44x | CN¥94.37 Million |
| 2017 | 9.87% | 15.76% | 0.53x | 1.19x | CN¥-2.42 Million |
| 2018 | 10.57% | 9.47% | 0.86x | 1.29x | CN¥11.07 Million |
| 2019 | 9.67% | 8.43% | 0.79x | 1.46x | CN¥-6.09 Million |
| 2020 | 1.65% | 2.19% | 0.54x | 1.40x | CN¥-148.20 Million |
| 2021 | 16.70% | 37.11% | 0.31x | 1.46x | CN¥140.81 Million |
| 2022 | 1.48% | 2.94% | 0.31x | 1.61x | CN¥-173.86 Million |
| 2023 | 3.44% | 6.21% | 0.34x | 1.61x | CN¥-140.39 Million |
| 2024 | 2.72% | 5.18% | 0.30x | 1.76x | CN¥-157.34 Million |
Industry Comparison
This section compares Harbin Medisan Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $3,632,405,673
- Average return on equity (ROE) among peers: 7.53%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Harbin Medisan Pharmaceutical Co Ltd (002900) | CN¥1.90 Billion | 24.63% | 0.89x | $459.69 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $1.97 Billion | 4.04% | 0.54x | $488.97 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $560.87 Million | 4.60% | 0.22x | $360.39 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.02 Billion | 12.46% | 0.13x | $4.73 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.04 Billion | 4.29% | 0.46x | $2.58 Billion |
| Wedge Industrial Co Ltd (000534) | $0.00 | 0.00% | 0.00x | $1.20 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $18.14 Billion | 17.33% | 0.53x | $14.52 Billion |
| Hainan Haiyao Co Ltd (000566) | $491.82 Million | 6.71% | 1.19x | $755.58 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $280.91 Million | 1.46% | 1.58x | $272.98 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $5.57 Billion | 7.36% | 1.59x | $920.83 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $7.25 Billion | 17.08% | 0.09x | $3.02 Billion |
About Harbin Medisan Pharmaceutical Co Ltd
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium foli… Read more